Market Overview:
The global nicotinic agonists market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Alzheimer’s disease (AD) and schizophrenia, and the growing demand for novel therapies for these diseases. Nicotine is currently the most commonly used nicotinic agonist in therapeutics, owing to its well-known effects on cognitive function and memory. However, acetylcholine, carbachol, epibatidine, and other nicotinic agonists are also being developed as potential treatments for various diseases. These drugs are being investigated for their potential use in treating a range of conditions such as AD, schizophrenia, pain relief, smoking cessation, and others. Regionally speaking North America dominates the global nicotinic agonists market followed by Europe due to high prevalence rates of AD and schizophrenia in these regions respectively .
Product Definition:
A nicotinic agonist is a drug that binds to and activates the nicotinic acetylcholine receptors in the brain. These drugs are used to treat conditions such as Alzheimer's disease, Parkinson's disease, and Tourette's syndrome. The importance of nicotinic agonists is that they can improve symptoms in patients with these diseases by increasing the activity of acetylcholine receptors in the brain.
Nicotine:
Nicotine is a chemical that is found in the leaves of tobacco and in some plants. It's main function is to protect the plant from being eaten by insects. Nicotine also helps the plant to grow, so that it can have more seeds to produce more tobacco for its master (the smoker). The amount of nicotine present in different types of cigarettes varies widely; one brand may have as much as 15 mg while another brand may contain only 2-3 mg.
Acetylcholine:
Acetylcholine is an important neuromuscular transmission chemical. It is also a precursor for the synthesis of many important pharmaceutical drugs such as paracetamol, phenoxyethanol, and ethanol (as well as some natural products). The global acetylcholine market size spans application areas in multiple sectors including healthcare & medical sector.
Application Insights:
The others segment dominated the global nicotinic agonists market in terms of revenue in 2017. This is due to the presence of products for other medical conditions such as Parkinson¢â‚¬â„¢s disease, multiple sclerosis, and diabetes. In addition, this segment also includes a product for smoking cessation which is yet to be approved by the U.S FDA under section Quaalude Tablets (umais) brand name.
Alzheimer¢â‚¬â„¢s disease (AD) application was one of the major segments that contributed significantly towards revenue growth in 2017 owing to increasing geriatric population base and rising prevalence rate across the globe.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high awareness levels regarding mental disorders, availability of effective treatment methods, and rising disposable income. Moreover, increasing government initiatives for nicotine replacement therapy (NRT) are also anticipated to boost product demand in this region. For instance, the U.S Food and Drug Administration (FDA) has approved two products under this brand name - Nicorette chewing gums that deliver nicotine via lozenges and Nicotinell nasal spray that contains a combination of bupropion hydrochloride and nicotinamide adenine dinucleotide phosphate (NADP).
Growth Factors:
- Increasing smoking population: The number of smokers is increasing globally, especially in the developing countries. This will drive the demand for nicotinic agonists as smoking cessation therapies.
- Rising awareness about the health hazards of smoking: There is a growing awareness among people about the health hazards of smoking. This is driving them to seek effective quitting methods, such as nicotinic agonists.
- Growing research and development activities: The pharmaceutical companies are investing heavily in research and development activities to develop better-quality nicotinic agonists products. This will help in expanding the market for these drugs in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nicotinic Agonists Market Research Report
By Type
Nicotine, Acetylcholine, Carbachol, Epibatidine, Others
By Application
Alzheimer's Disease (AD), Schizophrenia, Others
By Companies
FORUM Pharmaceuticals, Karuna Pharmaceuticals, Sumitomo Dainippon Pharma Co, BMS, Oyster Point Pharma, Jiangsu Hansoh Pharmaceutical, Dalian Meilun Biotech Co
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Nicotinic Agonists Market Report Segments:
The global Nicotinic Agonists market is segmented on the basis of:
Types
Nicotine, Acetylcholine, Carbachol, Epibatidine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alzheimer's Disease (AD), Schizophrenia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- FORUM Pharmaceuticals
- Karuna Pharmaceuticals
- Sumitomo Dainippon Pharma Co
- BMS
- Oyster Point Pharma
- Jiangsu Hansoh Pharmaceutical
- Dalian Meilun Biotech Co
Highlights of The Nicotinic Agonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nicotine
- Acetylcholine
- Carbachol
- Epibatidine
- Others
- By Application:
- Alzheimer's Disease (AD)
- Schizophrenia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nicotinic Agonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nicotinic agonists are drugs that bind to nicotinic receptors and cause a response in the body. These drugs can be used to treat conditions such as Alzheimer's disease, depression, and nicotine addiction.
Some of the major players in the nicotinic agonists market are FORUM Pharmaceuticals, Karuna Pharmaceuticals, Sumitomo Dainippon Pharma Co, BMS, Oyster Point Pharma, Jiangsu Hansoh Pharmaceutical, Dalian Meilun Biotech Co.
The nicotinic agonists market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nicotinic Agonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nicotinic Agonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nicotinic Agonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nicotinic Agonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nicotinic Agonists Market Size & Forecast, 2020-2028
4.5.1 Nicotinic Agonists Market Size and Y-o-Y Growth
4.5.2 Nicotinic Agonists Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Nicotine
5.2.2 Acetylcholine
5.2.3 Carbachol
5.2.4 Epibatidine
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Alzheimer's Disease (AD)
6.2.2 Schizophrenia
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nicotinic Agonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nicotinic Agonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Nicotine
9.6.2 Acetylcholine
9.6.3 Carbachol
9.6.4 Epibatidine
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Alzheimer's Disease (AD)
9.10.2 Schizophrenia
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Nicotine
10.6.2 Acetylcholine
10.6.3 Carbachol
10.6.4 Epibatidine
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Alzheimer's Disease (AD)
10.10.2 Schizophrenia
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Nicotine
11.6.2 Acetylcholine
11.6.3 Carbachol
11.6.4 Epibatidine
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Alzheimer's Disease (AD)
11.10.2 Schizophrenia
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Nicotine
12.6.2 Acetylcholine
12.6.3 Carbachol
12.6.4 Epibatidine
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Alzheimer's Disease (AD)
12.10.2 Schizophrenia
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Nicotine
13.6.2 Acetylcholine
13.6.3 Carbachol
13.6.4 Epibatidine
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Alzheimer's Disease (AD)
13.10.2 Schizophrenia
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nicotinic Agonists Market: Competitive Dashboard
14.2 Global Nicotinic Agonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 FORUM Pharmaceuticals
14.3.2 Karuna Pharmaceuticals
14.3.3 Sumitomo Dainippon Pharma Co
14.3.4 BMS
14.3.5 Oyster Point Pharma
14.3.6 Jiangsu Hansoh Pharmaceutical
14.3.7 Dalian Meilun Biotech Co
